ecancermedicalscience

Conference Report

Phase 0 workshop at the 20th EORTC-NCI-AACR symposium, Geneva

12 Nov 2008
S Camporesi

Are phase 0 clinical trials really necessary?

This question was posed by James Doroshow (National Cancer Institute, Bethesda, USA) at the 20th EORT-NCI-AARC Symposium on Molecular Targets and Cancer Therapeutics (Geneva, 21–24 October 2008). Together with E Leo (Beerse, Belgium), James Doroshow-since 2004 Director of the Division of Cancer Treatment and Diagnosis at NCI-was co-chairing the workshop on phase 0 clinical trials. In his introduction to the speakers, Doroshow raised six open questions, namely whether phase 0 trials are useful, ethically acceptable, feasible, whether they speed up the drug development process and save money, and whether there is room for improvement.

Related Articles

Berthe Sabine Esson Mapoko, Andreas Frambo, Yauba Saidu, Esther Dina Bell Mbassi, Etienne Atenguena, Kareen Azemafac, Emily Kobayashi, Lionel Tabola, Glenda Nkeng, Anne Sango, Anne Marthe Maison, Sidonie Ananga Noa, Ambroise Ntama, Ruth Rosine Meka’h Mapenya, Rachel Tayou, Francine Kouya, Glenn Mbah, Pelagie Douanla, Celestin Fonkwa, Martin Essomba Biwole, Zacharie Sando, Albert Mouelle Sone, Paul Ndom
Glenn M Afungchwi, Elianeth Kiteni, Mariam Ndagire, Biemba Maliti, Rachael Kunkel, Julia M Challinor, Rachel Hollis
Raunaq Puri, Madhup Rastogi, Ajeet Kumar Gandhi, Rohini Khurana, Rahat Hadi, Shantanu Sapru, Anshuman Pandey, Akash Agarwal, Anoop Kumar Srivastava, Surendra Prasad Mishra, Farhana Khatoon, Avinav Bharati, Vachaspati Kumar Mishra, Akanksha Manral, Prasoon Mishra
Annie Kanchan Baa, Atul Sharma, Suman Bhaskar, Ahitagni Biswas, Alok Thakar, Rajeev Kumar, Sreeja Jayant, Gourishankar Aland, Alain D’Souza, Vikas Jadhav, Atul Bharde, Jayant Khandare, Raja Pramanik
Uchenna Simon Ezenkwa, Gabriel Olabiyi Ogun, Mbwas Isaac Mashor, Olufemi John Ogunbiyi